(9R)-Megastigmane-4-one glucoside

(9R)-O-β-D-glucopyranosyloxy-2,5-megastigmen-4-one is a C13-norisoprenoid glucoside whose aglycone megastigmanone core is hypothesized to modulate inflammatory signaling, likely through inhibition of pro-inflammatory cytokine production and suppression of NF-κB–mediated transcriptional pathways, consistent with activity observed in structurally analogous megastigmane glycosides. Preliminary in vitro screening has assigned this compound an IC50 exceeding 100 µM in lipopolysaccharide-induced macrophage models, indicating weak anti-inflammatory activity at concentrations that would be pharmacologically challenging to achieve in vivo.

Origin & History

Megastigmane glycosides including (9R)-O-β-D-glucopyranosyloxy-2,5-megastigmen-4-one are secondary metabolites biosynthesized primarily in vascular plants as carotenoid degradation products, frequently isolated from species in the families Asteraceae, Rosaceae, Convolvulaceae, and Solanaceae. Their formation arises from oxidative cleavage of carotenoid precursors such as β-carotene and zeaxanthin, with subsequent glycosylation at the C-9 hydroxyl position yielding water-soluble glucoside conjugates. These compounds are distributed across leaf, flower, fruit, and root tissues depending on the source plant, and their geographic prevalence mirrors that of carotenoid-rich flora in temperate and tropical regions worldwide.

Historical & Cultural Context

Megastigmane compounds as a chemical class have not been historically recognized or deliberately utilized in traditional medicine systems under their structural nomenclature, as their identification is a product of modern phytochemical analysis beginning in the latter half of the 20th century. Plants producing megastigmane glycosides — including species of Rosa, Osmanthus, Buddleja, and various Ipomoea — have long histories of use in Ayurvedic, Traditional Chinese Medicine, and European herbal traditions for their broader anti-inflammatory, tonic, and aromatic properties, but attributing these effects specifically to megastigmane constituents was not possible before modern chromatographic and spectroscopic techniques. The volatile aglycone forms of related megastigmanes such as β-ionone and damascenone are well-known flavor and fragrance compounds historically valued in perfumery and culinary traditions, particularly in rose attar and wine flavor chemistry. The glycosidic form studied here represents a non-volatile, water-soluble storage form that would have been consumed unknowingly through dietary plant intake without specific cultural recognition.

Health Benefits

- **Weak Anti-inflammatory Activity**: The compound exhibits IC50 >100 µM against LPS-stimulated inflammatory mediator production in macrophage cell lines; while statistically detectable, this potency is substantially below the threshold considered pharmacologically meaningful for drug development, placing it in the category of mild modulators rather than potent anti-inflammatory agents.
- **Antioxidant Potential (Structural Inference)**: Megastigmane aglycones carry an α,β-unsaturated ketone moiety at C-4 and conjugated double bonds that theoretically confer electrophilic reactivity toward reactive oxygen species; however, direct DPPH or ORAC values for this specific stereoisomer have not been independently reported in peer-reviewed literature.
- **Carotenoid Metabolite Bioactivity**: As a product of carotenoid catabolism, this compound may contribute to the broader biological effects attributed to carotenoid-rich diets, including modulation of cellular redox status and attenuation of oxidative stress-linked gene expression, although these effects have not been isolated and quantified for this specific glucoside.
- **Possible Cytokine Modulation**: Structurally related megastigmane glycosides, such as 9ξ-O-β-D-glucopyranosyloxy-5-megastigmen-4-one (IC50 30.3 ± 2.1 µM), suppress TNF-α and IL-6 secretion in macrophage models; by structural analogy, the (9R) isomer may exert comparable but attenuated effects, though direct cytokine profiling data are absent.
- **Glycoside Solubility and Bioavailability Advantage**: The β-D-glucopyranosyl moiety at C-9 renders this otherwise lipophilic megastigmanone scaffold substantially more water-soluble than its aglycone, potentially improving gastrointestinal absorption upon oral administration, pending hydrolysis by intestinal β-glucosidases to release the active aglycone.
- **Phytochemical Marker Value**: This compound serves as a chemotaxonomic marker for certain plant species and can be used in quality control fingerprinting of botanical extracts via HPLC-MS/MS, contributing to the standardization of botanical ingredient preparations even when its direct pharmacological contribution is modest.

How It Works

The proposed mechanism of (9R)-O-β-D-glucopyranosyloxy-2,5-megastigmen-4-one begins with intestinal hydrolysis of the β-D-glucopyranosyl moiety by mucosal β-glucosidases, liberating the aglycone (9R)-megastigma-2,5-dien-4-one, which is the presumed bioactive form. The enone system within the aglycone may act as a Michael acceptor capable of covalently modifying cysteine residues on redox-sensitive signaling proteins such as Keap1, potentially activating Nrf2-driven antioxidant response element (ARE) gene transcription, a mechanism documented for related α,β-unsaturated carbonyl-containing natural products. Additionally, suppression of NF-κB nuclear translocation and consequent downregulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression has been observed for structurally analogous megastigmane compounds in macrophage models, and is the most plausible explanation for the weak IC50 value recorded for this specific isomer. The stereochemistry at C-9 (R-configuration) influences receptor or enzyme binding geometry relative to the S or racemic forms, but comparative stereochemical bioactivity data for megastigmane glucosides remain sparse in the published literature.

Scientific Research

The scientific evidence base for (9R)-O-β-D-glucopyranosyloxy-2,5-megastigmen-4-one consists almost exclusively of phytochemical isolation reports and preliminary in vitro bioactivity screening, representing the lowest tier of pharmacological evidence. No controlled human clinical trials, animal efficacy studies, or pharmacokinetic investigations appear to have been conducted specifically with this stereoisomeric compound as of the available literature. The IC50 >100 µM anti-inflammatory value places this compound below the threshold of pharmacological interest for drug development, and the available data are most commonly generated as part of broad compound library screenings accompanying plant extract characterization studies rather than targeted mechanistic investigations. The most relevant comparative data derive from a structurally related compound (9ξ-O-β-D-glucopyranosyloxy-5-megastigmen-4-one), which demonstrated an IC50 of 30.3 ± 2.1 µM in LPS-induced macrophage assays, illustrating how minor structural differences among megastigmane isomers can produce meaningful differences in bioactivity.

Clinical Summary

There are no published clinical trials involving (9R)-O-β-D-glucopyranosyloxy-2,5-megastigmen-4-one as an isolated compound or standardized ingredient administered to human subjects. The sole quantified bioactivity datum is an IC50 exceeding 100 µM in an in vitro macrophage inflammatory model, a value that does not support clinical translation without substantially more preclinical validation, including dose-response characterization, selectivity profiling, and in vivo pharmacokinetic/pharmacodynamic studies. Clinical confidence in any health benefit attributable to this specific compound is therefore extremely low, and any therapeutic claims would be premature and unsupported by current evidence. Researchers interested in the clinical potential of megastigmane glucosides should focus investigative resources on more potent analogs with IC50 values in the low-micromolar range before advancing to human trials.

Nutritional Profile

As a pure isolated phytochemical compound rather than a whole food or standardized extract, (9R)-O-β-D-glucopyranosyloxy-2,5-megastigmen-4-one does not have a conventional macronutrient or micronutrient profile. Its molecular formula is C19H32O7 (molecular weight approximately 372.45 g/mol), comprising a C13 terpenoid aglycone backbone esterified with a glucose sugar unit, providing negligible caloric value in the quantities present in plant tissues. In source plants, this compound co-occurs with carotenoids (β-carotene, lutein, zeaxanthin), flavonoid glycosides, phenolic acids, and other norisoprenoid metabolites, and its bioavailability is dependent on hydrolysis by intestinal β-glucosidases (analogous to the activation pathway for other plant glucosides such as isoflavone glycosides). Absolute quantitative concentration data in plant tissues are compound- and species-specific and have not been systematically reported for this stereoisomer across food-relevant plant matrices.

Preparation & Dosage

- **Research-Grade Isolation**: Typically obtained via preparative HPLC or column chromatography from plant methanol or ethanol extracts; purity ≥95% confirmed by NMR and HRESIMS; no commercial supplement form established.
- **Effective Dose**: No clinically validated or traditionally established dose exists; in vitro activity is only detectable at concentrations exceeding 100 µM, which is not achievable through conventional oral dosing of crude plant extracts.
- **Plant Extract Context**: When consumed as part of a whole botanical preparation (e.g., tea or tincture from a source plant), this compound would be present in trace quantities far below any pharmacologically active threshold identified in vitro.
- **Standardization**: No commercial extract standardized to this specific compound is currently available; its presence may be detected as part of carotenoid metabolite profiling but is not used as a primary marker for extract potency.
- **Timing and Administration**: No evidence-based timing or administration protocol exists; current use is restricted to laboratory research settings.

Synergy & Pairings

No empirically validated synergistic combinations have been reported for (9R)-O-β-D-glucopyranosyloxy-2,5-megastigmen-4-one in the scientific literature, given the early-stage nature of its characterization. By mechanistic inference, compounds that enhance β-glucosidase activity in the gut — such as probiotic strains producing microbial glucosidases (e.g., Lactobacillus and Bifidobacterium species) — could improve aglycone liberation and thus enhance bioavailability of the active form following oral administration, analogous to the established bioavailability enhancement of isoflavone glycosides by intestinal microbiota. Co-administration with other NF-κB–modulating compounds such as curcumin or resveratrol could theoretically produce additive anti-inflammatory effects through complementary pathway modulation, though such combinations have not been tested for this specific megastigmane glucoside.

Safety & Interactions

No formal toxicological assessment, including acute or chronic toxicity studies, genotoxicity assays, or safety pharmacology profiling, has been published specifically for (9R)-O-β-D-glucopyranosyloxy-2,5-megastigmen-4-one as an isolated compound. Given its trace-level occurrence in edible plants and its structural classification as a carotenoid degradation product — a compound class with a long history of human dietary exposure without known toxicity — it is unlikely to present significant safety concerns at levels obtained through normal plant food consumption. No drug interaction data exist for this specific compound; however, compounds that modulate NF-κB signaling or Nrf2 pathways, as hypothesized for its aglycone, could theoretically interact with immunosuppressant drugs, anticoagulants, or corticosteroids if administered at pharmacologically relevant doses, which is not currently achievable. Pregnancy and lactation safety data are entirely absent, and as with all insufficiently characterized phytochemicals, avoidance of high-dose isolated compound supplementation during pregnancy is prudent pending further safety characterization.